Arena is a biopharmaceutical company focused on discovering and developing novel, small molecule drugs. We are currently directing our activities and resources primarily on:
Display all Answers
We plan to report on BELVIQ’s performance during our quarterly financial results announcements.
Subscription services that are available for a fee track and provide BELVIQ prescription data. At times, this information is reported on by the research analyst community and media.
Arena’s fiscal year ends on December 31.
You can sign up for email alerts to receive notification of announcements and upcoming events here.
At this time Arena does not offer a direct stock purchase plan.
Jul 14, 2016
Eisai and Arena Pharmaceuticals Announce Regulatory Approval of VENESPRI® (lorcaserin HCl) in Mexico
Jun 30, 2016
Arena Pharmaceuticals Announces Shift to Focus on Proprietary Clinical Stage Pipeline
There are no upcoming events available at this time.
You are now leaving arenapharm.com and being directed to a site not maintained by Arena. Arena is not responsible for content or privacy policies on other sites.